A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early-intensified treatments) would be more efficacious than the current second-line treatments (treatment as usual) for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.

开始日期2025-04-30

申办/合作机构

Universität Leipzig

ChiCTR2500099510

/ SuspendedN/AIIT

A modeling predictive study of clinical factors associated with lithium on treatment responsiveness in patients with bipolar disorder

开始日期2025-04-01

申办/合作机构

中南大学湘雅医院

NCT05973786

/ Recruiting临床3期IIT

A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Bipolar disorders affect approximately 4.5 million people across the European Union (EU) and are associated with high annual healthcare and societal costs. Bipolar disorder I and II represent disorders that cause extreme fluctuation in a person's mood, energy, and ability to function, in which symptoms of (hypo)mania and depression alternate. The depressive episodes of bipolar disorders are often referred to as bipolar depression (BD). In other words: it is a phase/state of the disorder. For many patients with BD, the depressive polarity is often more pervasive and more debilitating than manic states, with estimates that depressed mood accounts for up to two-thirds of the time spent unwell, even with treatment. The burden of not received an effective treatment for BD is high: more severe psychopathology, higher rates of unemployment, more hospitalisations, lower quality of life, lower cognitive functioning, risk of suicide, comorbidities and poorer social and occupational functioning and thus more carer burden. For BD, the treatment guidelines are very heterogeneous, amongst other reasons because the disease is heterogeneous and treatments should be tailored to the patients. There is no clear treatment algorithm and it cannot yet be predicted which treatment will be effective. Especially the place of adjunctive antidepressants is under debate. Usually, for psychiatric disorders (including bipolar disorder), a patient is considered to be treatment-resistant is two medicinal treatments have been tried (in sufficient duration and dosage) without sufficient success. For BD, there is no consensus on when to consider a patient as treatment-resistant, but the most common definition is after one prior treatment failure. This raises the research question whether adjunctive antidepressants to treat BD should be introduced earlier in the treatment. Additionally, The INTENSIFY trial is part of the larger Horizon 2021 project, with the central goal of paving the way for a shift towards a treatment decision-making process tailored for the individual at risk for treatment resistance. To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for treatment resistance across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression.

开始日期2025-02-11

申办/合作机构

Universität Leipzig

100 项与 Lithium succinate 相关的临床结果

登录后查看更多信息

100 项与 Lithium succinate 相关的转化医学

登录后查看更多信息

100 项与 Lithium succinate 相关的专利（医药）

登录后查看更多信息

62,195

项与 Lithium succinate 相关的文献（医药）

2025-08-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

An efficient approach to probe bioactive components of herbal patches by 2D-carbon microfiber fractionation and multi-chamber membrane separation electrophoresis: Spatholobus suberectus Dunn as a case

Article

作者: Shang, Hai-Bo ; Cui, Haiyan ; Shao, Miao ; Yang, Lei ; Zhu, Yuwei ; Li, Donghao ; Liu, Huwei ; Liu, Yonglong ; Qiu, Yu ; Quinto, Maurizio ; Nardiello, Donatella ; Cui, Meiyu

Herbal patches are widely used in clinics for their good curative effects. However, due to the complexity of plant matrices and the extremely low content of transdermal components, the individuation of their effective bioactive compounds represents a challenge: there is then a great need for an efficient method to reveal the bioactive ingredients of herbal patches. In this work, a wide-screening approach is proposed to an individuation of transdermal bioactive components in herbal patches obtained by Spatholobus suberectus Dunn (S. suberectus). Using a two-dimensional microscale carbon fiber/active carbon fiber system combined with a quadrupole time-of-flight high-resolution mass spectrometry (2DµCFs-QTOF-HRMS), a rapid and comprehensive analysis, lasting only 5 min, allowed the identification of 45 distinct polar components within S. suberectus extracts. Among these, 30 components exhibited a transdermal penetration estimated at values higher than 10 %. The key target, predicted by bioinformatics, was prostaglandin-endoperoxide synthase 2 (PTGS2). From the transdermal components of S. suberectus, four potential inhibitors of PTGS2 (protocatechuic acid, isoliquiritigenin, medicarpin, and catechin) were screened by multi-chamber membrane separation electrophoresis (MCMSE). The presence of binding pockets and action sites for medicarpin, isoliquiritigenin, and catechin determines higher binding energy towards PTGS2, with lower IC₅₀ values (12.27, 9.08, and 41.68 μM, respectively). The high-throughput and high-sensitivity analysis by 2DµCFs-QTOF-HRMS, combined with a high-accuracy screening of MCMSE, provides strong technical support for the discovery of trace transdermal bioactive components of herbal patches. The integration of the two technologies could accelerate the study of action mechanisms, quality control, and product improvement of herbal patches.

2025-08-01·JOURNAL OF AFFECTIVE DISORDERS

Lithium and lamotrigine for the treatment of bipolar II disorder – a systematic review and meta-analysis of randomized trials

Review

作者: Vinberg, Maj ; Fredskild, Mette Ungermann ; Bruun, Caroline Fussing ; Munkholm, Klaus ; Kessing, Lars Vedel ; Faurholt-Jepsen, Maria

OBJECTIVES:

This systematic review and meta-analysis aimed to synthesize the evidence from randomized trials of lithium, lamotrigine, and placebo for the treatment of bipolar II disorder (BDII) in terms of bipolar II depression, hypomania, and maintenance treatment.

METHODS:

A literature search was performed 20th November 2024 across PubMed, Embase and PsycINFO, and grey literature for studies of lithium, lamotrigine, and placebo in adults with BDII, across illness phases. Primary outcomes were efficacy and tolerability. We conducted random-effects pair-wise meta-analysis to provide a summary measure of effect, assessed the risk of bias, and assessed the certainty of the evidence using the GRADE framework.

RESULTS:

Our search yielded 2326 records, including 10 randomized trials comprising 645 patients with BDII. The evidence was very uncertain regarding lithium's effect on the risk of new affective episodes, regardless of polarity, compared with placebo (RR 0.86, 95 % CI [0.66, 1.11], I² = 0 %, four studies, very low certainty evidence). A quantitative synthesis could not be conducted to compare lamotrigine and placebo. The evidence was very uncertain regarding the effect of lithium on depression severity compared with lamotrigine (mean HAMD17 difference: 1.27, 95 % CI [-3.84, 6.38], I² = 0 %, two studies, very low certainty evidence). The overall risk of bias was of 'some concern' for 84 % of outcomes assessed. For all outcomes, the certainty of the evidence was graded 'very low'.

CONCLUSION:

The evidence for lithium and lamotrigine in treating BDII is scarce, and the certainty of the evidence is very low. Large, well-conducted RCTs of patients with BDII are needed.

2025-08-01·FOOD CHEMISTRY

Exploring the influence of fruit ripeness on the microbiome, bioactive components, and flavor profiles of naturally fermented noni (Morinda citrifolia L.) juice

Article

作者: Liu, Sixin ; Su, Congyan ; Li, Congfa ; Kang, Jiamu

Raw fruit ripeness is an important factor affecting fermented noni fruit juice (FNJ). This study investigated the physicochemical properties, active and volatile components, microbiota, and functional characteristics of FNJ prepared from noni fruits at varying ripening stages. The results showed that deacetylasperulosidic acid (203.54-805.89 mg/L) and asperulosidic acid (102.78-393.41 mg/L) were detected across in all FNJs during fermentation. As noni fruit ripens, the levels of octanoic acid and hexanoic acid in FNJs gradually decreased, while the content of esters significantly increased, particularly during the final stage of ripeness. Metagenomic analysis revealed that Acetobacter sp. and Gluconobacter sp. were core microbes responsible for FNJs, primarily contributing to fatty acid metabolism. Correlation analysis further indicated that the fruit's ripeness significantly influenced its functional properties and volatile components of FNJs. This study offered new insights into selecting the optimal ripeness of noni fruits for the preparation of FNJ and its potential industrial applications.

171

项与 Lithium succinate 相关的新闻（医药）

2025-05-13

·ir.alzamend.com

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 13, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the initiation of the first of five Phase II clinical studies of AL001, with the first study in healthy human subjects. This study follows the successful development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore the unique properties of AL001 and its potential to deliver lithium more effectively in the brain compared to marketed lithium salts. The study in healthy human subjects will serve as a baseline and assist Alzamend determine the best path forward in Alzheimer’s, BD, MDD and PTSD patients by demonstrating AL001’s targeted effectiveness and reduced systemic side effects. Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments. By offering a treatment that potentially eliminates the need for lithium therapeutic drug monitoring (“TDM”), AL001 could revolutionize care for vulnerable patient populations and improve treatment outcomes. Lithium, renowned for its efficacy as a first-line therapy for manic episodes and maintenance in BD, has long been underutilized due to the complexities of TDM. Current U.S. Food and Drug Administration-approved lithium salts are limited by a narrow therapeutic window that requires regular TDM of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events. Since conventional lithium salts are eliminated relatively quickly, multiple administrations throughout the day are required to safely reach therapeutic plasma concentrations. By reducing the systemic burden, Alzamend’s novel AL001 formulation could signify a major shift in managing conditions like Alzheimer’s, by minimizing risks associated with kidney and thyroid side effects traditionally linked to lithium therapies. “With AL001, we can potentially introduce a next-generation lithium treatment that offers enhanced safety, better brain targeting, and no need for TDM, promising a leap forward from the current, burdensome options,” stated Stephan Jackman, Chief Executive Officer of Alzamend. “This advancement stands to potentially enhance the lives of over 43 million Americans suffering from Alzheimer’s, BD, MDD and PTSD by providing a safer, more effective and user-friendly therapeutic option, potentially reshaping current treatment paradigms and improving patient quality of life substantially.” About AL001 AL001 is a novel lithium-delivery system that has the potential to provide the benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium. Results from Alzamend’s completed Phase IIA multiple-ascending dose study of AL001 in Alzheimer’s patients and healthy subjects identified a maximum tolerated dose (“MTD”), as assessed by an independent safety review committee. This MTD is designed to be unlikely to require TDM while providing lithium at a relatively modest but effective dose. AL001 is designed to favorably distribute lithium in the brain resulting in lower exposure of other body organs and an improved safety profile compared to currently marketed lithium salts. This can serve to mitigate or obviate the disadvantageously low ceiling for toxicity of marketed lithium salts that has limited their usefulness to patients and prescribers. About Alzamend Neuro Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s by removing beta-amyloid from the brain. The latter is a second-generation active-immunity approach designed to mitigate the disadvantages of approved passive immunity marketed antibody products, particularly by reducing the required frequency and costs of dosing associated with antibody products. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com. Contacts: Email: Info@Alzamend.com or call: 1-844-722-6333 Released May 13, 2025

临床2期临床结果疫苗

2025-05-08

·GlobeNewswire-Health Care

Alzamend Neuro Announces Reverse Stock Split

ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that Alzamend’s board of directors approved a one-for-nine reverse stock split of Alzamend’s common stock (“Common Stock”) that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on May 12, 2025. Beginning with the opening of trading on May 12, 2025, the Company’s Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company’s existing trading symbol “ALZN”. The new CUSIP number for the Common Stock will be 02262M605. The reverse stock split is part of the Company’s plan to maintain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits. The reverse stock split affects all issued and outstanding shares of the Company’s Common Stock, as well as the number of shares of Common Stock available for issuance under the Company’s equity incentive plans. In addition, the reverse stock split reduces the number of shares of Common Stock issuable upon the exercise of stock options or warrants outstanding immediately prior to the reverse split. The par value of the Company’s Common Stock will remain unchanged at $0.0001 per share after the reverse stock split. The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment. As of the date of this press release, Alzamend has 7,208,591 shares of Common Stock issued and outstanding, which it anticipates will result in approximately 800,954 shares of Common Stock after the reverse stock split is effective. Computershare Trust Company, N.A. (“Computershare”), is acting as the exchange agent and transfer agent for the reverse stock split. Computershare will provide instructions to stockholders for receiving payment for any fractional shares. About Alzamend Neuro Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s by removing beta-amyloid from the brain. The latter is a second-generation active-immunity approach designed to mitigate the disadvantages of approved passive immunity marketed antibody products, particularly by reducing the required frequency and costs of dosing associated with antibody products. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com. Contacts:Email: Info@Alzamend.com or call: 1-844-722-6333

疫苗

2025-05-07

·GlobeNewswire-Health Care

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its partnership with Mint Labs Inc. d/b/a QMENTA (“QMENTA”), a leading medical imaging artificial intelligence (“AI”) company, to support its five upcoming Phase II clinical trials of AL001 at Massachusetts General Hospital. QMENTA’s cloud-based platform will manage and analyze medical imaging data throughout the trials, ensuring regulatory compliance, enhancing operational efficiency and supporting data management. Their advanced AI solutions will play a critical role in optimizing the imaging workflow across all five clinical studies. In collaboration with QMENTA and Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore the unique properties of AL001 and its potential to deliver lithium more effectively in the brain compared to marketed lithium salts. The study in healthy human subjects will serve as a baseline and assist Alzamend determine the best path forward in Alzheimer’s, BD, MDD and PTSD patients by demonstrating AL001’s targeted effectiveness and reduced systemic side effects. Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments. By offering a treatment that potentially eliminates the need for lithium therapeutic drug monitoring (“TDM”), AL001 could revolutionize care for vulnerable patient populations and improve treatment outcomes. Lithium, renowned for its efficacy as a first-line therapy for manic episodes and maintenance in BD, has long been underutilized due to the complexities of TDM. Current U.S. Food and Drug Administration-approved lithium salts are limited by a narrow therapeutic window that requires regular TDM of plasma lithium levels and blood chemistry by a clinician to mitigate adverse events. Since conventional lithium salts are eliminated relatively quickly, multiple administrations throughout the day are required to safely reach therapeutic plasma concentrations. By reducing the systemic burden, Alzamend’s novel AL001 formulation could signify a major shift in managing conditions like Alzheimer’s, by minimizing risks associated with kidney and thyroid side effects traditionally linked to lithium therapies. “QMENTA has developed an all-in-one management platform for medical imaging clinical trials incorporating advancing AI solutions,” said Stephan Jackman, Chief Executive Officer of Alzamend. “We are thrilled to add QMENTA to the team and have full confidence in their ability encompassing our five phase II clinical studies of AL001. Moreover, this collaboration lays a foundation for future phase III programs and broader clinical deployment of advanced AI-based imaging biomarkers.” “It’s a privilege to collaborate with Alzamend on such groundbreaking work. I truly believe that the right imaging strategy combined with innovative compounds like AL001 will transform how we treat complex neurodegenerative diseases and psychiatric disorders,” said Vesna Prchkovska, Chief Executive Officer of QMENTA. “By applying AI-driven imaging technologies, we believe we can advance safer, more effective treatments that could significantly impact patients with Alzheimer’s, BD, MDD, PTSD, among other diseases.” About Alzamend Neuro Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s by removing beta-amyloid from the brain. The latter is a second-generation active-immunity approach designed to mitigate the disadvantages of approved passive immunity marketed antibody products, particularly by reducing the required frequency and costs of dosing associated with antibody products. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend’s website at www.Alzamend.com. Contacts:Email: Info@Alzamend.com or call: 1-844-722-6333 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c01526b6-40ac-41bf-915f-059f857184a3

临床2期疫苗

100 项与 Lithium succinate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Lithium succinate	D11AX04	DB14508

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
脂溢性皮炎	英国	-	1990-01-01
特应性皮炎	英国	Scotia Holdings Plc	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳头状瘤病毒感染	临床2期	英国	Scotia Holdings Plc	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ENDO2024	N/A	甲状腺功能亢进症 \| 粒细胞减少症 TSH receptor antibodies (TRAb)	-	Lithium	繭齋糧願獵範窪製鏇襯(齋鏇觸衊蓋艱鹹範鑰鏇) = Carbimazole-induced agranulocytosis 餘構鹽艱鹽選選遞淵廠 (鬱觸廠顧鹹淵蓋築蓋襯 ) 更多	-	2024-06-01
				Carbimazole
ATS2024	N/A	气肿	-	Lithium users	簾遞襯選艱觸鑰鹹範觸(範憲膚憲壓壓製範獵鑰) = 廠鑰觸餘壓築襯築顧簾鹹觸夢膚獵餘糧餘醖餘 (鏇構淵夢餘築壓壓壓鬱 )	-	2024-05-19
ATS2023	N/A	气肿	-	Lithium users	淵遞廠構積鏇鹹繭餘襯(淵衊築衊衊遞範選糧窪) = 繭顧獵鏇餘築淵鏇醖醖製觸鬱廠襯鏇廠餘顧繭 (襯蓋鹽糧遞齋鑰鹽鏇齋 ) 更多	-	2023-05-21
				Non-users	淵遞廠構積鏇鹹繭餘襯(淵衊築衊衊遞範選糧窪) = 選壓廠選簾艱簾憲餘鬱製觸鬱廠襯鏇廠餘顧繭 (襯蓋鹽糧遞齋鑰鹽鏇齋, 0.4 ~ 0.9) 更多
ASGCT2023	N/A	-	-	Lithium	憲壓鹹夢鬱蓋衊遞選餘(齋遞鏇餘簾範襯齋膚醖) = 觸構願鹹鏇蓋鹹鏇糧選顧鏇衊鬱齋蓋衊襯壓築 (遞顧願夢鏇憲餘壓齋鬱 ) 更多	积极	2023-05-01
ASN2022	N/A	肾性尿崩症	-	Lithium	壓遞蓋積壓艱鹹衊積壓(艱淵蓋築餘醖餘遞鏇餘) = 廠網觸築製遞醖廠艱遞淵鏇淵廠憲鏇鑰壓壓鏇 (構顧築鏇遞蓋範獵獵襯 ) 更多	-	2022-11-06
				Desmopressin	壓餘獵憲齋廠鬱蓋廠繭(鏇膚淵獵鹽鹽夢壓艱憲) = 獵廠鏇構鹹衊簾範齋蓋觸蓋壓積顧醖鏇網鏇顧 (壓醖願窪範蓋觸糧製憲 )
ASN2022	N/A	肾性尿崩症	-	Lithium Carbonate 300 mg	製壓鏇齋構廠鹹鹽鹽鏇(選膚壓衊製鬱窪願糧鬱) = 範壓夢選範醖壓製鑰憲築範淵鹽範淵鏇築餘範 (夢衊鹹廠觸觸餘餘鹽窪 )	-	2022-11-06
				Thiazide diuretic	製壓鏇齋構廠鹹鹽鹽鏇(選膚壓衊製鬱窪願糧鬱) = 夢製壓築鹽餘鹽淵選淵築範淵鹽範淵鏇築餘範 (夢衊鹹廠觸觸餘餘鹽窪 )
ASN2022	N/A	急性肾损伤	2,682	Lithium-treated group	襯齋衊簾糧構夢繭夢網(鹽遞餘築壓顧獵繭網蓋) = 範遞衊膚餘襯積壓範夢衊襯積範糧艱襯觸窪艱 (顧簾構壓積艱願築膚鑰 )	积极	2022-11-04
				Lithium (Control group)	襯齋衊簾糧構夢繭夢網(鹽遞餘築壓顧獵繭網蓋) = 齋築鬱鑰衊夢窪築膚糧衊襯積範糧艱襯觸窪艱 (顧簾構壓積艱願築膚鑰 )
MDS2022	N/A	帕金森病 Nurr1 \| SOD1	16	High-dose lithium therapy	襯顧願鹽淵願糧憲鹽糧(醖淵餘獵齋範選築獵獵) = 築艱壓選膚醖範選選廠淵鏇鹹顧齋鹽膚衊艱鬱 (衊遞鑰醖襯簾製衊淵繭 )	-	2022-09-15
				Medium-dose lithium therapy	襯顧願鹽淵願糧憲鹽糧(醖淵餘獵齋範選築獵獵) = 蓋衊艱鏇齋夢簾蓋襯壓淵鏇鹹顧齋鹽膚衊艱鬱 (衊遞鑰醖襯簾製衊淵繭 )
ISN WCN2022	N/A	中毒 \| 间质性肾炎	-	Lithium carbonate 900 mg/day	膚壓願築壓壓艱廠願築(選鹹齋簾簾鬱觸鏇夢製) = The diagnosis of chronic interstitial nephritis was made based on suggestive clinical and biological signs 醖鹹簾選顧網齋糧鹽齋 (選餘夢顧憲鹹餘範壓醖 )	-	2022-02-01
				No lithium therapy
ASN2021	N/A	-	2,682	Lithium-treated group	醖構蓋餘醖鬱衊製鏇膚(淵鏇製構遞憲醖淵選觸) = 鹹觸選膚簾製網醖鏇範襯餘製觸製網製選範窪 (鬱簾網憲顧餘壓鑰獵鏇 )	不佳	2021-10-27
				Lithium (Control group)	醖構蓋餘醖鬱衊製鏇膚(淵鏇製構遞憲醖淵選觸) = 廠艱範遞築製醖糧艱積襯餘製觸製網製選範窪 (鬱簾網憲顧餘壓鑰獵鏇 )